Editorial Board

A. Seth Editor-in-Chief Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada

J.G. Delinassios Managing Editor and Executive Publisher, International Institute of Anticancer Research, Athens, Greece

L.A. Aaltonen Department of Medical Genetics, University of Helsinki, Finland

S. Aaronson Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA

R. Abagyan The Scripps Research Institute, La Jolla, CA, USA

F. Ahmed Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA

J.D. Aitchison Institute for Systems Biology, Seattle, WA, USA

W. Ansorge IAET, Borex, Switzerland

S. Antonarakis Division of Medical Genetics, University of Geneva Medical School, Switzerland

F.G. Barr Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

A.M. Burger Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

A.M. Chinnaiyan Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

B.F.C. Clark Department of Molecular Biology, University of Aarhus, Denmark

R. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA

I. Dunham The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK

N.A. Ellis Department of Medicine University of Chicago, IL, USA

J.A. Fernandes-Pol Metallomics, LLC, Chesterfield, MO, USA

C. Forst McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA

M. Fountoulakis F. Hoffman-La Roche Pharmaceutical Research, Basel, Switzerland

W.L. Gerald Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J.W. Gray Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA

B.B. Haab Van Andel Research Institute, Grand Rapids, MI, USA

C.-H. Heldin Ludwig Institute for Cancer Research, Uppsala, Sweden

J.D. Hoheisel Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany

R.P. Huang Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA

T.H.M. Huang Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA

Y. Ito Institute of Molecular and Cell Biology, Oncology Research Institute, Yon Loo Lin School of Medicine, National University of Singapore, Singapore

V.C. Jordan Fox Chase Cancer Center, Philadelphia, PA, USA

J. Ju Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA

A. Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland

O.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland

M. Kanehisa Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan

S.E. Kern Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA

K. Khalili College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA

D.G. Kieback Department of Obstetrics and Gynecology, HELIOS Medical Center, Carl Gustav Carus University, Dresden, Germany

S.D. Kotzarakis Department of Virology, Hellenic Anticancer Institute, Athens, Greece

B. Leyland-Jones Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA

P. Lichter Deutsches Krebsforschungszentrum, Heidelberg, Germany

A. Lindblom Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden

G. Lubeck Department of Pediatrics, University of Vienna, Austria

J. Lyons-Weiler Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA

P.J. McCormick The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA

J.D. Minna Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA

F. Mitelman Department of Clinical Genetics, University Hospital, Lund, Sweden

P. Nelson Fred Hutchinson Cancer Research Center, Seattle, WA, USA

C. Nicot Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA

L. O’Driscoll School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:
International Institute of Anticancer Research
1st km Kapandritio-Kalamou Road,
P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
Tel: +30 22950 52945, Fax: +30 22950 53389
e-mail: journals@iiar-anticancer.org. Website: www.iiar-anticancer.org; www.cgp-journal.com

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandriti-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org; editor@cgp-journal.com

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: 416 480 5737, e-mail: genomics.proteomics@utoronto.ca
Contents

Immune Response Signatures of Benzo(α)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (Morgantown, WV; Bethesda, MD; Triangle Park, NC, USA) ................................................................. 1

Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes Using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (Giessen, Germany) .................................................. 13


Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M.YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (Bethesda, Frederick, MD; San Jose, CA; Houston, TX, USA) .................................................................................................... 41

Abstracts of the 3rd International Conference of the Hellenic Proteomics Society, March 30 - April 1, 2009 ................................................................................................................................. 51

Erratum ................................................................................................................................. 73
Instructions to Authors

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in CGP, for public archiving in PubMed Central.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated with confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

Copyright. On publication of a manuscript in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 2000 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.


Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. You can send your article via e-mail to journals@iiaar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. OR You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delineasios, International Institute of Anticancer Research (IAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS. 1st km Kapandriti-Kalamou Road, P.O. Box 22, GR-19014, Kapandriti, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.